Pharmacodynamics and clinical use of anti-HIV drugs.
Antiretroviral drug exposure has been linked to both antiviral efficacy and the development of toxicity and further research in this area is ongoing and necessary. Use of these data may have important implications for TDM of HAART regimens in clinical practice. TDM, in conjunction with an assessment of the patient's viral resistance in the form of an IQ, needs to be examined and validated in large clinical trials.
Preston
Sandra L
SL
Clinical Research Institute, Division of Clinical Pharmacology, Albany Medical College, 47 New Scotland Avenue, mc142, Albany, NY 12208, USA. prestos@mail.amc.edu
Piliero
Peter J
PJ
Drusano
George L
GL
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000502:physiology; D019380:Anti-HIV Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D019540:Area Under Curve; D001682:Biological Availability; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage; D006207:Half-Life; D006801:Humans; D011485:Protein Binding
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors